Cargando…

Nurse empowerment through Pharmacogenetics

OBJECTIVE: to verify the existence of elements that justify the use of pharmacogenetics by the Brazilian nurse. METHOD: this is a quantitative, cross-sectional, observational, descriptive study, whose final sample was 67 individuals. The participants were healthy at the time of the study and reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: de Moraes, Jordana Carvalhaes, Nunes, Fernanda Daniela Dornelas, Coeli-Lacchini, Fernanda Borchers, Miyazaki, Anderson Heiji Lima, Flória-Santos, Milena, Lacchini, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426146/
https://www.ncbi.nlm.nih.gov/pubmed/32813781
http://dx.doi.org/10.1590/1518-8345.3415.3265
_version_ 1783570625014530048
author de Moraes, Jordana Carvalhaes
Nunes, Fernanda Daniela Dornelas
Coeli-Lacchini, Fernanda Borchers
Miyazaki, Anderson Heiji Lima
Flória-Santos, Milena
Lacchini, Riccardo
author_facet de Moraes, Jordana Carvalhaes
Nunes, Fernanda Daniela Dornelas
Coeli-Lacchini, Fernanda Borchers
Miyazaki, Anderson Heiji Lima
Flória-Santos, Milena
Lacchini, Riccardo
author_sort de Moraes, Jordana Carvalhaes
collection PubMed
description OBJECTIVE: to verify the existence of elements that justify the use of pharmacogenetics by the Brazilian nurse. METHOD: this is a quantitative, cross-sectional, observational, descriptive study, whose final sample was 67 individuals. The participants were healthy at the time of the study and reported a history of previous use and the occurrence of adverse effects by drugs commonly used and metabolized by CYP2C9. We collected 4 mL of venous blood for subsequent DNA extraction by salting out method and genotyping of the CYP2C9*2 and CYP2C9*3 polymorphisms, using Polymerase Chain Reaction in real time using Taqman assays. RESULTS: the use of drugs metabolized by CYP2C9 was frequent (more than 75% of the individuals have already used between 2 or 4 of these drugs). Regarding adverse events, there were 19 perceived symptomatic occurrences associated with drugs metabolized by CYP2C9. The allele frequency of the polymorphism * 2 and * 3 in the population studied was 11.1% and 7.5%, respectively, and there was a coincidence between the presence of alleles of low enzyme activity and the occurrence of adverse effects. CONCLUSION: there are elements that justify the adoption of pharmacogenetics in the nursing care to reduce the occurrence of adverse reactions to drugs metabolized by CYP2C9.
format Online
Article
Text
id pubmed-7426146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-74261462020-08-25 Nurse empowerment through Pharmacogenetics de Moraes, Jordana Carvalhaes Nunes, Fernanda Daniela Dornelas Coeli-Lacchini, Fernanda Borchers Miyazaki, Anderson Heiji Lima Flória-Santos, Milena Lacchini, Riccardo Rev Lat Am Enfermagem Original Article OBJECTIVE: to verify the existence of elements that justify the use of pharmacogenetics by the Brazilian nurse. METHOD: this is a quantitative, cross-sectional, observational, descriptive study, whose final sample was 67 individuals. The participants were healthy at the time of the study and reported a history of previous use and the occurrence of adverse effects by drugs commonly used and metabolized by CYP2C9. We collected 4 mL of venous blood for subsequent DNA extraction by salting out method and genotyping of the CYP2C9*2 and CYP2C9*3 polymorphisms, using Polymerase Chain Reaction in real time using Taqman assays. RESULTS: the use of drugs metabolized by CYP2C9 was frequent (more than 75% of the individuals have already used between 2 or 4 of these drugs). Regarding adverse events, there were 19 perceived symptomatic occurrences associated with drugs metabolized by CYP2C9. The allele frequency of the polymorphism * 2 and * 3 in the population studied was 11.1% and 7.5%, respectively, and there was a coincidence between the presence of alleles of low enzyme activity and the occurrence of adverse effects. CONCLUSION: there are elements that justify the adoption of pharmacogenetics in the nursing care to reduce the occurrence of adverse reactions to drugs metabolized by CYP2C9. Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo 2020-08-12 /pmc/articles/PMC7426146/ /pubmed/32813781 http://dx.doi.org/10.1590/1518-8345.3415.3265 Text en Copyright © 2020 Revista Latino-Americana de Enfermagem https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
de Moraes, Jordana Carvalhaes
Nunes, Fernanda Daniela Dornelas
Coeli-Lacchini, Fernanda Borchers
Miyazaki, Anderson Heiji Lima
Flória-Santos, Milena
Lacchini, Riccardo
Nurse empowerment through Pharmacogenetics
title Nurse empowerment through Pharmacogenetics
title_full Nurse empowerment through Pharmacogenetics
title_fullStr Nurse empowerment through Pharmacogenetics
title_full_unstemmed Nurse empowerment through Pharmacogenetics
title_short Nurse empowerment through Pharmacogenetics
title_sort nurse empowerment through pharmacogenetics
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426146/
https://www.ncbi.nlm.nih.gov/pubmed/32813781
http://dx.doi.org/10.1590/1518-8345.3415.3265
work_keys_str_mv AT demoraesjordanacarvalhaes nurseempowermentthroughpharmacogenetics
AT nunesfernandadanieladornelas nurseempowermentthroughpharmacogenetics
AT coelilacchinifernandaborchers nurseempowermentthroughpharmacogenetics
AT miyazakiandersonheijilima nurseempowermentthroughpharmacogenetics
AT floriasantosmilena nurseempowermentthroughpharmacogenetics
AT lacchiniriccardo nurseempowermentthroughpharmacogenetics